Literature DB >> 9811711

T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.

H Sakaida1, T Hori, A Yonezawa, A Sato, Y Isaka, O Yoshie, T Hattori, T Uchiyama.   

Abstract

Certain types of chemokine receptors have been identified as coreceptors for HIV-1 infection. The process of viral entry is initiated by the interaction between an envelope protein gp120 of HIV-1, CD4, and one of the relevant coreceptors. To understand the precise mechanism of the Env-mediated fusion and entry of HIV-1, we examined whether the V3 region of gp120 of T-cell line tropic (T-tropic) virus directly interacts with the coreceptor, CXCR-4, by using five synthetic V3 peptides: two cyclized V3 peptides (V3-BH10 and V3-ELI) which correspond to the V3 regions of the T-tropic HIV-1 IIIB and HIV-1 ELI strains, respectively, a linear V3 peptide (CTR36) corresponding to that of HIV-1 IIIB strain; and cyclized V3 peptides corresponding to that of the macrophage-tropic (M-tropic) HIV-1 ADA strain (V3-ADA) or the dualtropic HIV-1 89.6 strain (V3-89. 6). FACScan analysis with a CXCR-4(+) human B-cell line, JY, showed that V3-BH10, V3-ELI, and V3-89.6 but not CTR36 or V3-ADA blocked the binding of IVR7, an anti-CXCR-4 monoclonal antibody (MAb), to CXCR-4 with different magnitudes in a dose-dependent manner, while none of the V3 peptides influenced binding of an anti-CD19 MAb at all. Next, the effects of the V3 peptides on SDF-1beta-induced transient increases in intracellular Ca2+ were investigated. Three V3 peptides (V3-BH10, V3-ELI, and V3-89.6) prevented Ca2+ mobilization. Furthermore, the three peptides inhibited infection by T-tropic HIV-1 in a dose-dependent manner as revealed by an MTT assay and a reverse transcriptase assay, while the other peptides had no effects. These results present direct evidence that the V3 loop of gp120 of T-tropic HIV-1 can interact with its coreceptor CXCR-4 independently of the V1/V2 regions of gp120 or cellular CD4.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811711      PMCID: PMC110487     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

4.  Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones.

Authors:  H Yssel; J E De Vries; M Koken; W Van Blitterswijk; H Spits
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

5.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

6.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

7.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

8.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

Authors:  Y Hinuma; K Nagata; M Hanaoka; M Nakai; T Matsumoto; K I Kinoshita; S Shirakawa; I Miyoshi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-10       Impact factor: 11.205

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  17 in total

1.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120.

Authors:  E G Cormier; M Persuh; D A Thompson; S W Lin; T P Sakmar; W C Olson; T Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

4.  Inactivation of human immunodeficiency virus type 1 by porphyrins.

Authors:  Andrei N Vzorov; Dabney W Dixon; Jenna S Trommel; Luigi G Marzilli; Richard W Compans
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

Authors:  T Murakami; T Y Zhang; Y Koyanagi; Y Tanaka; J Kim; Y Suzuki; S Minoguchi; H Tamamura; M Waki; A Matsumoto; N Fujii; H Shida; J A Hoxie; S C Peiper; N Yamamoto
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.

Authors:  A Yonezawa; T Hori; A Takaori-Kondo; R Morita; T Uchiyama
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Peptide-Based HIV Entry Inhibitors.

Authors:  Jing Pu; Qian Wang; Shibo Jiang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

9.  Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans.

Authors:  Laurence Panicot-Dubois; Grace M Thomas; Barbara C Furie; Bruce Furie; Dominique Lombardo; Christophe Dubois
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein.

Authors:  Magnus Sundstrom; Rebecca L White; Aymeric de Parseval; K Jagannadha Sastry; Garrett Morris; Chris K Grant; John H Elder
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.